BioReg­num: An­oth­er great rea­son emerges for As­traZeneca to tar­get new biotech deals

Bioreg­num
The view from End­points

The pres­sure on As­traZeneca CEO Pas­cal So­ri­ot to get its glob­al R&D op­er­a­tion to per­form while ex­e­cut­ing new deals just soared. The phar­ma gi­ant has lost a bid to keep cheap gener­ic ver­sions of Crestor off the mar­ket. That drug earned some $5 bil­lion of the $23 bil­lion it made last year.

To put this in­to a per­spec­tive that must be in­creas­ing­ly un­com­fort­able at the phar­ma gi­ant, As­traZeneca will soon have a new, block­buster-sized hole to fill as in­vestors con­tin­ue to in­sist that the com­pa­ny keep its promise to hit $45 bil­lion in sales in just sev­en more years.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.